Trials / Withdrawn
WithdrawnNCT00517491
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
A Pilot Study to Evaluate the Correlation Between Plasma Lanreotide Levels and GH/IGF-1 Dynamics and Clinical Improvement in Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the protocol is to evaluate the correlation between plasma lanreotide levels and Growth Hormone (GH)/Insulin Like Growth Factor 1 (IGF-1) dynamics and clinical improvement in patients with acromegaly treated with lanreotide Autogel (Somatuline ATG)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lanreotide (Autogel formulation) | 120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study. |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2007-08-17
- Last updated
- 2019-08-05
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT00517491. Inclusion in this directory is not an endorsement.